Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial

• Eugene Kim,
• Federico Cappuzzo,
• Martin Reck,
• Wei Zou,
• Mark A Socinski,
• Mark McCleland,
• Makoto Nishio,
• Stefanie Morris,
• David Shames,
• Meghna Das Thakur,
• Tony SK Mok,
• Howard Jack West,
• Robert M Jotte,
• Geetha Shankar

Affiliations

Eugene Kim

Department of Anesthesiology and Critical Care Medicine, Children`s Hospital of Los Angeles, Los Angeles, California, USA

Federico Cappuzzo

Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy

Martin Reck

Lungen Clinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany

Wei Zou

Department of Biostatistics Oncology, Genentech Inc, South San Francisco, California, USA

Mark A Socinski

Thoracic Oncology, AdventHealth Cancer Institute, Orlando, Florida, USA

Mark McCleland

Department of Oncology Biomarker Development, Genentech Inc, South San Francisco, California, USA

Makoto Nishio

Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan

Stefanie Morris

Product Development Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland

David Shames

Genentech Inc, South San Francisco, California, USA

Meghna Das Thakur

Department of Development Sciences, Genentech, San Francisco, California, USA

Tony SK Mok

15Clinical Oncology, State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Shatin, Hong Kong, China

Howard Jack West

Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA

Robert M Jotte

Department of Medical Oncology, Rocky Mountain Cancer Centers, Denver, Colorado, USA

Geetha Shankar

Genentech Inc, South San Francisco, California, USA